Cariotipo de alta resolución en sangre periférica en la Neurofibromatosis 1 / High Resolution Karyotype in Peripheral Blood in Neurofibromatosis 1

Miladys Orraca Castillo, Araceli Lantigua Cruz, Deysi Licourt Otero

Texto completo:

PDF HTML

Resumen

La Neurofibromatosis tipo 1 (NF1) es uno de los desórdenes autosómicos dominantes más comunes y está causado por defectos en el gen NF1 situado en el cromosoma 17q11.2. Se realizó un estudio descriptivo y transversal en pacientes con NF1 en Pinar del Río durante el año 2005, con el objetivo de identificar en cariotipos de alta resolución defectos cromosómicos y relacionarlos con las características clínicas-radiológicas encontradas, seleccionando 42 pacientes con NF1, asociado a dismorfias, retraso mental, degeneración maligna, neurofibromas plexiformes y tumores del SNC. El 4,7% presentó cariotipo anormal. Las alteraciones estructurales que involucran el gen de la NF1 conllevan a una mayor severidad clínica de la enfermedad.

Palabras claves: NEUROFIBROMATOSIS/ GEN NF1/ CARIOTIPO.

ABSTRACT

The Neurofibromatosis Type-1 (NF1) is one of the most common autosomal dominant disorders and it is provoked by a defect in the NF1 gene located in chromosome 17q11.2. A descriptive, cross-sectional study in patients carrying NF1 in Pinar del Rio was carried out during 2005 aimed at identifying the high resolution karyotypes of chromosomic defects to relate them to the clinical-radiologic features found, to perform it 42 patients carrying NF1 associated with dysmorphia, mental retardation, malignant degeneration, plexiform neurofibromas and tumors in the CNS were chosen. 4, 7% showed abnormal karyotype. The structural changes involving the NF1-gene lead to a greater clinical severity of the disease.

Key words: Neurofibromatosis, gene-NF1, karyotype

Referencias

"Por la Vida": Estudio psicosocial de las personas con discapacidades y estudio psicopedagógico, social y clínico-genético de las personas con retraso mental en Cuba. Ciudad de la Habana: casa editora Abril; 2003.

Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrolment. Arch Dermatol. 2005; 141(1):78-9.

Gutmann DH, Collins FS. Neurofibromatosis 1. En: Scriver Ch R, Beaudet AL, Sly WS, Valle D dir. The Metabolic-Molecular Bases of Inherited Disease.8th ed. New York: McGraw-Hill; 2001.p. 877-896.

Kehrer-Sawatzki H, Kluwe L, Sandig C, Kohn M, Wimmer K, Krammer V et.al. High frecuency of mosaicism among patients with neurofibromatosis type 1(NF 1) with microdeletions caused by somatic recombination of the JJAZ 1 gene. Am J Hum Genet 2004; 75(3):410-23.

Bernheim A, Dessen Philipe, Huret JL, et al.Genes, locations y Genetic Disorders on Cromosoma.Disponible en: http://www.infobiogen.fr/services/chromcancer. 17 monografia en internet acceso el 19 de junio del 2006.

Cnossen MH, Vander MN, Breuning MH, Van Asperen CJ, Breslau-Siderius EJ, Halley DJ et al. Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type1.Hum Mutat.2004; 9:458-464.

Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-Sawatzki H et al.Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF 1 gene. Hum Mutat.2004; 23(2):111-6.

Upadhyaya M, Han S, Consoli C, Majonnie E, H oran M, Thomas NS etal. Caracterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF 1) gene in neurofibromatosis patients with benign and malignant tumors. Hum Mut.2004; 23(2):134-46.

Carroll SL, Stonecypher MS. Tumor suppressor mutations and growth factor signalling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: 2. the role of dysregulated growth factor signaling. J Neuropathol Exp Neurol.2005; 64(1):1-9.

Venturin MI, Guarnieri PI, Natacci F, Stabile M, Tenconi R, Clementi M et al. Mental Retardation and cardiovascular malformations in NF1 microdeleted patients point to candidate genes in 17q11.2. J Medical Genetics.2004; 41:35-41.

Bridge JR, Bridge JA, Neff JR, Naumann S, Ahhof P, Bruch LA. Recurrent chromosomal imbalances and structurally abnormal breakpoint within complex karyotypes of malignant peripheral nerve sheath tumour and malignant triton tumour: a cytogenetic and molecular cytogenetic study. J Clinical Pathology.2004; 57:1172-1178.

De Luca A, Bernardini L, Ceccarini C, Sinibaldi L, Novelli A, Giustini S et.al. Fluorescence in situ hibridization analysis of allelic losses involving the longarm of chromosome 17 in NF 1- associated neurofibromas. Cancer Genet Cytogenet.2004; 150(2):168-72.

Mueller RF, Young Ian D. Trastornos Monogénicos en Emery´s Genética Médica; 10 ed; Marbán; 2001.p 265-672.

Mashour GA, Driever PH, Hartmann M, Drissel SN, Shang T, Scharf B et.al. Circulating growth factor levels are associated with tumorogenesis in neurofibromatosis type 1. Clin Cancer Res.2004; 10(17):5677-83.

Huson SM, Rasser EM. The Phacomatoses. En: Emery EH, Rimoins D dir. Principles and Practice of Medical Genetics; 4th ed;United Kingdom: Churchill Livingstone; 2002.Pp.1861-1898.

Las neurofibromatosis (monografía en Internet). Nacional Institute of Neurological Disorders and Stroke; Disponible en: http://www.ninds.nih.gov/health and medical/pubs/Las neurofibromatosis.htm. acceso el 22 de julio del 2005.

De Luca A, Schirinzi A, Buccino A, Bottillo I, Sinibaldi L, Torrente I etal. Novel and recurrent mutations in the NF 1 gene in Italian patients with neurofibromatosis type 1. Hum Mut.2004; 23(6):629.

Lazaro C, Ars E, Serra E, Estivill x. Bases moleculares de la Neurofibromatosis Tipo 1. En: Pascual CI dir. Neurofibromatosis. Madrid: Fundación ONCE; 2001.p.249-251.

González GN. Inversión Pericéntrica del 9 y 9qh+. ¿Variantes Cromosómicas? (Tesis para optar por el Título de Master en Genética Médica). Ciudad de la Habana: Centro Nacional de Genética Médica; 2003.



Copyright (c) 1969 Miladys Orraca Castillo, Araceli Lantigua Cruz, Deysi Licourt Otero

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional.